Entrada Therapeutics, Inc. (TRDA) has a negative trailing P/E of -4.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -24.80%.
Criteria proven by this page:
Overall SharesGrow Score: 61/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -5.4 | 0.00 | -1.62 | 0.00 | - |
| 2020 | -28.2 | 0.35 | -18.04 | 0.00 | - |
| 2021 | -10.4 | -0.12 | 1.79 | 0.00 | - |
| 2022 | -4.5 | -0.06 | 1.99 | 0.00 | - |
| 2023 | -74.6 | 0.80 | 2.06 | 3.87 | - |
| 2024 | 9.8 | -0.01 | 1.50 | 3.06 | - |
| 2025 | -3.0 | 0.01 | 1.39 | 16.73 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.15 | $0.00 | $-4.65M | - |
| 2020 | $-0.84 | $0.00 | $-26.38M | - |
| 2021 | $-1.60 | $0.00 | $-50.07M | - |
| 2022 | $-2.79 | $0.00 | $-87.46M | - |
| 2023 | $-0.20 | $129.01M | $-6.69M | -5.2% |
| 2024 | $1.68 | $210.78M | $65.63M | 31.1% |
| 2025 | $-3.47 | $25.42M | $-143.75M | -565.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.91 | $-4.16 – $-3.22 | $24.92M | $12.4M – $41.34M | 6 |
| 2027 | $-3.69 | $-4.57 – $-2.87 | $30.06M | $20.26M – $39.86M | 6 |
| 2028 | $-3.49 | $-5.16 – $-1.26 | $66.68M | $64.91M – $68.44M | 5 |
| 2029 | $-2.85 | $-4.61 – $-1.35 | $86.67M | $51.63M – $127.74M | 1 |
| 2030 | $-1.91 | $-3.09 – $-0.91 | $243.8M | $145.24M – $359.32M | 1 |
